Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma
Yi Luo(Kunming Institute of Botany), Zhongyu Yuan(Sun Yat-sen University), Ming Hong(Guangzhou University of Chinese Medicine), Qi Wang(Hebei Medical University), Xinyu Wang(Jiangsu University), Yongqiang Liu(Ningbo University), Yujie Huang(Guangzhou University of Chinese Medicine), Lei Song(Capital Medical University)
Cited by 39
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study
|The Lancet Public Health|2020|1.8k
Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer’s disease
|Journal of Structural Biology|2005|585
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Heritability and genomics of gene expression in peripheral blood
|Nature Genetics|2014|424